

## Dhanuka Agritech

*Monsoon abnormality dents the show; maintaining a Buy*

Lower agrochemical demand primarily due to stressed demand drivers like a) weather issues, b) low crop prices etc. has in turn resulted into subdued performance for Dhanuka Agritech during Q3. Revenue/EBITDA/PAT declined by 8/22/27% y/y due to lower farm income and reduced spending on crop protection products, impacting domestic sales. Further, farmers shifted towards inferior products due to lower crop and horticulture prices aggravating the situation. Demand decline were evident in South and West India. Other key highlights: a) Sales return almost flat y/y during Q3FY26 at Rs720mn v/s Rs740mn during the same period last year, b) Rs30m Dahej revenue and Rs50m EBITDA loss. c) 9M FY26 innovation-turnover index 16.3% (16.6% a year back); d) WC marginally on the higher side post 3Q'26 largely on the back of higher inventory due to lower liquidation.

**Quarterly Performance Highlights:** Gross margin fell by a mere 10bps y/y to 39.8% (vs. ARe of 38.8%), aided by a slightly better product-mix. Further, opex rose by 100bps y/y, while employee expenses increased by 140bps y/y due to one-time impact of Rs2.5m due to New Labour Code), including further reimbursement of Rs60m royalty from Bayer AG for two new products (Rs195m in 9MFY26), led to EBITDA margin contraction of 260bps y/y to 14.4% (vs. ARe of 15%). Absolute EBITDA fell 22% y/y to Rs589mn (vs. ARe of Rs594m).

**Product Launches on Track; Benefits to Accrue:** Sales volume of newly launched products i.e., Dinkar (paddy herbicide), Lanevo (insecticide), and Mycore Super (PGR) was healthy. The management is upbeat about these, and aims at decent market shares along with Turmoil, Rockstar and Purge etc.

**Outlook and Valuation:** Climate abnormality and low crop prices in consumption period led to lower agrochemicals offtake and lower-than-expected performance in 9MFY26. Hence, the management has trimmed guidance for FY26. Further, slower start to Rabi season due to delayed Kharif season added to the woes. Considering sluggish 9MFY26 performance and lower guidance, we trim our EPS estimate by 12/7/7% for FY26/27/28e and maintain BUY rating on the stock with a revised TP of Rs1,350 (from Rs1,530 earlier), valuing it at 17x FY28e EPS (vs. 18x FY28e EPS previously). **Key Risks:** (a) Adverse weather condition; and (b) volatility in commodity prices; and (c) undue delay in ramping up the Dahej plant.

Key Financials (Y/E Mar)	FY24	FY25	FY26e	FY27e	FY28e
Sales (Rs m)	17,585	20,352	20,034	22,738	25,713
Net profit (Rs m)	2,391	2,970	2,669	3,149	3,568
EPS (Rs)	52.5	65.9	59.2	69.9	79.2
P/E (x)	20.5	16.3	18.2	15.4	13.6
EV / EBITDA (x)	14.2	11.3	11.7	9.6	7.9
P/BV (x)	3.9	3.5	3.0	2.6	2.2
RoE (%)	20.6	22.3	17.6	17.7	17.2
RoCE (%)	27.6	29.3	23.4	23.9	23.2
Dividend yield (%)	1.3	0.4	0.6	0.7	0.7
Net debt / equity (x)	-0.2	-0.1	-0.3	-0.3	-0.4

Source: Company, Anand Rathi Research

Anand Rathi Share and Stock Brokers Limited (hereinafter "ARSSBL") is a full-service brokerage and equities-research firm and the views expressed therein are solely of ARSSBL and not of the companies which have been covered in the Research Report. This report is intended for the sole use of the Recipient. Disclosures and analyst certifications are present in the Appendix.

Rating: **BUY**

Target Price (12-mth): Rs.1,350


Share Price: Rs.1,075

Key Data	DAGRI IN / DHNP.BO
52-week high / low	Rs1975 / 1018
Sensex / Nifty	83314 / 25643
Market cap	Rs48bn
Shares outstanding	45m

Shareholding Pattern (%)	Dec'25	Sep'25	Jun'25
Promoters	69.7	69.7	69.9
- of which, Pledged	0.0	0.0	0.0
Free float	30.3	30.3	30.1
- Foreign institutions	2.1	2.3	2.7
- Domestic institutions	18.8	18.1	17.6
- Public	9.4	9.9	9.8

Estimates Revision (%)	FY26e	FY27e	FY28e
Sales	(5.7)	(7.2)	(7.0)
EBITDA	(10.6)	(7.0)	(6.8)
PAT	(11.7)	(7.4)	(7.2)

### Relative Price Performance



Source: Bloomberg

**Himanshu Binani**  
Research Analyst

## Quick Glance – Financial and Valuations (Consolidated)

**Fig 1 – Income Statement (Rs m)**

Y/E Mar	FY24	FY25	FY26e	FY27e	FY28e
Revenues	17,585	20,352	20,034	22,738	25,713
Growth (%)	3.4	15.7	-1.6	13.5	13.1
Raw material	10,722	12,191	12,060	13,916	15,736
Employee & other expen.	3,589	3,995	4,147	4,329	4,915
<b>EBITDA</b>	<b>3,274</b>	<b>4,166</b>	<b>3,826</b>	<b>4,493</b>	<b>5,061</b>
EBITDA margins (%)	18.6	20.5	19.1	19.8	19.7
- Depreciation	406	555	589	636	664
Other income	350	361	379	398	418
Interest expense	31	51	48	45	45
PBT	3,188	3,921	3,569	4,210	4,770
Effective tax rates (%)	25	24	25	25	25
+ Associates / (Minorities)	-	-	-	-	-
Adj. income	2,391	2,970	2,669	3,149	3,568
Extraord. items (loss)/profit	-	-	-	-	-
Rep. PAT	2,391	2,970	2,669	3,149	3,568
WANS	46	45	45	45	45
FDEPS (Rs)	52.5	65.9	59.2	69.9	79.2

**Fig 3 – Cash-flow Statement (Rs m)**

Y/E Mar	FY24	FY25	FY26e	FY27e	FY28e
PBT	3,188	3,921	3,569	4,210	4,770
+ Non-cash items	436	606	637	681	709
Oper. profit before WC changes	3,624	4,527	4,205	4,891	5,479
- Incr. / (decr.) in WC	1,208	674	-343	539	507
Others incl. taxes	1,071	1,227	1,278	1,459	1,620
Operating cash-flow	1,344	2,627	3,270	2,894	3,352
- Capex (tangible + intangible)	1,125	1,772	965	1,000	600
Free cash-flow	219	855	2,305	1,894	2,752
Acquisitions	-	-	-	-	-
- Div. (incl. buyback & taxes)	501	323	326	380	380
+ Equity raised	-	-	-	-	-
+ Debt raised	-33	417	-422	-	-
- Fin. investments	-316	-344	-379	-398	-418
- Misc. items (CFI and CFF)	31	1,293	48	45	45
Net cash-flow	-30	1	1,888	1,867	2,745

Source: Company, Anand Rathi Research

**Fig 5 – Price Movement**



Source: Bloomberg

**Fig 2 – Balance Sheet (Rs m)**


Y/E Mar	FY24	FY25	FY26e	FY27e	FY28e
Share capital	91	90	90	90	90
Net worth	12,559	14,027	16,371	19,140	22,328
Debt	5	422	-	-	-
Minority interest	-	-	-	-	-
Deferred tax liability/(asset)	51	48	48	48	48
<b>Capital employed</b>	<b>12,614</b>	<b>14,497</b>	<b>16,419</b>	<b>19,188</b>	<b>22,377</b>
Net tangible assets	3,381	5,042	5,453	5,817	5,753
CWIP (tang. and intang.)	282	85	50	50	50
Investments (strategic)	1,678	1,068	1,068	1,068	1,068
Investments (financial)	718	1,236	1,236	1,236	1,236
Current assets (excl. C&CE)	9,719	10,557	10,443	11,469	12,495
Cash	13	14	1,902	3,769	6,514
Current liabilities	3,177	3,504	3,733	4,220	4,740
Working capital	6,542	7,053	6,710	7,249	7,755
<b>Capital deployed</b>	<b>12,614</b>	<b>14,497</b>	<b>16,419</b>	<b>19,188</b>	<b>22,377</b>

**Fig 4 – Ratio Analysis**

Y/E Mar	FY24	FY25	FY26e	FY27e	FY28e
P/E (x)	20.5	16.3	18.2	15.4	13.6
EV / EBITDA (x)	14.2	11.3	11.7	9.6	7.9
EV / Sales (x)	2.6	2.3	2.2	1.9	1.6
P/B (x)	3.9	3.5	3.0	2.6	2.2
RoE (%)	20.6	22.3	17.6	17.7	17.2
RoCE (%) - after tax	27.6	29.3	23.4	23.9	23.2
RoIC (%) - after tax	21.2	23.4	18.2	18.6	19.7
DPS (Rs)	14.0	4.0	6.0	7.0	7.0
Dividend yield (%)	1.3	0.4	0.6	0.7	0.7
Dividend payout (%)	32.1	7.3	12.2	12.1	10.6
Net debt / equity (x)	-0.2	-0.1	-0.3	-0.3	-0.4
Receivables (days)	71	72	83	77	78
Inventory (days)	130	122	120	109	105
Payables (days)	55	43	42	39	40
CFO : PAT (%)	56	88	122	92	94

Source: Company, Anand Rathi Research

**Fig 6 – Zone-wise Revenue Share (Q3FY26)**



Source: Company

**Fig 7 – Zone and Category-wise Revenue Break-up**

(Rs m)	Q4 FY24	Q1FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26
<b>Zone-wise</b>								
North	958	1,530	1,897	1,008	1,503	1,638	1,795	1,025
West	737	2,073	1,832	1,228	884	2,166	1,436	1,230
East	516	395	785	498	530	475	778	451
South	1,473	938	2,028	1,720	1,503	1,004	1,974	1,394
<b>Total</b>	<b>3,683</b>	<b>4,936</b>	<b>6,543</b>	<b>4,453</b>	<b>4,420</b>	<b>5,283</b>	<b>5,982</b>	<b>4,099</b>
<b>Growth (%)</b>								
North	-11.0	38.2	27.9	13.6	56.9	7.0	-5.4	1.7
West	4.4	37.0	-12.8	12.8	20.0	4.5	-21.6	0.2
East	26.3	18.9	15.5	2.9	2.9	20.4	-0.9	-9.4
South	-3.2	27.0	5.9	9.3	2.0	7.0	-2.7	-19.0
<b>Total</b>	<b>-0.8</b>	<b>33.7</b>	<b>5.9</b>	<b>10.4</b>	<b>20.0</b>	<b>7.0</b>	<b>-8.6</b>	<b>-7.9</b>
<b>Category-wise</b>								
Herbicides	1,031	2,468	1,112	1,546	1,414	2,641	538	1,517
Insecticides	1,621	1,234	2,813	1,335	1,680	1,215	2,752	1,148
Fungicides	589	494	1,374	889	575	581	1,735	861
Others	442	740	1,243	683	751	845	957	574
<b>Total</b>	<b>3,683</b>	<b>4,936</b>	<b>6,543</b>	<b>4,453</b>	<b>4,420</b>	<b>5,283</b>	<b>5,982</b>	<b>4,099</b>
<b>Growth (%)</b>								
Herbicides	6.8	23.8	-28.0	9.5	37.2	7.0	-51.6	-1.9
Insecticides	-5.1	23.8	3.5	3.5	3.6	-1.5	-2.2	-14.0
Fungicides	-6.6	33.7	23.5	5.0	-2.5	17.7	26.3	-3.1
Others	8.2	122.9	54.8	41.2	70.0	14.2	-23.0	-16.0
<b>Total</b>	<b>-0.8</b>	<b>33.7</b>	<b>5.9</b>	<b>10.4</b>	<b>20.0</b>	<b>7.0</b>	<b>-8.6</b>	<b>-7.9</b>

Source: Company

**Fig 8 – Quarterly Trend**

(Rs m)	Q3FY26	Q3FY25	YoY (%)	Q2FY26	q/q (%)	9MFY26	9MFY25	y/y (%)	FY26E	FY25	y/y (%)
Revenue	4,099	4,453	(7.9)	5,982	(31.5)	15,365	15,931	(3.6)	20,034	20,352	(1.6)
Raw material	2,467	2,674	(7.7)	3,443	(28.3)	9,290	9,682	(4.0)	12,060	12,191	(1.1)
Staff costs	447	423	5.5	479	(6.6)	1,392	1,319	5.6	1,803	1,721	4.8
Others	596	600	(0.6)	694	(14.1)	1,894	1,862	1.7	2,344	2,274	3.1
Expenditure	3,510	3,697	(5.1)	4,615	(23.9)	12,576	12,863	(2.2)	16,208	16,185	0.1
EBITDA	589	756	(22.0)	1,367	(56.9)	2,788	3,069	(9.1)	3,826	4,166	(8.2)
Depreciation	163	131	24.5	163	(0.0)	479	380	26.0	589	555	6.1
EBIT	427	625	(31.8)	1,205	(64.6)	2,309	2,688	(14.1)	3,238	3,611	(10.4)
Less: Interest expense	8	14	(44.5)	8	(2.9)	29	33	(12.1)	48	51	(6.1)
Add: Other income	81	70	15.8	63	28.6	225	249	(9.9)	379	361	5.0
Profit before tax	500	681	(26.6)	1,260	(60.3)	2,505	2,905	(13.8)	3,569	3,921	(9.0)
Less: Provision for tax	97	130	(25.3)	320	(69.6)	608	690	(11.9)	899	952	(5.5)
Adj. profit	402	550	(26.9)	940	(57.2)	1,897	2,215	(14.3)	2,669	2,970	(10.1)
Add: Exceptional items	-3	0	NA	0	NA	-3	0	NA	-	-	
Rep. profit	400	550	(27.3)	940	(57.4)	1,895	2,215	(14.4)	2,669	2,970	(10.1)
Equity capital (FV: Rs 2)	90	90		90		90	90		90	90	
No. of diluted shares outstanding (m)	45	45		45		45	45		45	45	
Adj. diluted EPS (Rs)	8.9	12.2	(26.9)	20.9	(57.2)	42.1	49.1	(14.3)	59.3	65.9	(10.1)
<b>As % of net revenue</b>											
Raw material	60.2	60.1		57.6		60.5	60.8		60.2	59.9	
Staff expenses	10.9	9.5		8.0		9.1	8.3		9.0	8.5	
Other expenses	14.5	13.5		11.6		12.3	11.7		11.7	11.2	
EBITDA	14.4	17.0		22.9		18.1	19.3		19.1	20.5	
Net profit	9.8	12.4		15.7		12.3	13.9		13.3	14.6	

Source: Company

## Outlook and Valuation


Climate abnormality and low crop prices in consumption period led to lower agrochemicals offtake and lower-than-expected performance in 9MFY26. Hence, the management has trimmed guidance for FY26. Further, slower start to Rabi season due to delayed Kharif season added to the woes. **Thus, considering sluggish 9MFY26 performance and lower guidance, we trim our EPS estimate by 12/7/7% for FY26/27/28e and maintain BUY rating on the stock with a revised TP of Rs1,350 (from Rs1,530 earlier), valuing it at 17x FY28e EPS (vs. 18x FY28e EPS previously).**

**Fig 9 – Change in Estimates**

(Rs m)	FY26e			FY27e			FY28e		
	Old	New	Change (%)	Old	New	Change (%)	Old	New	Change (%)
Revenue	21,255	20,034	(5.7)	24,507	22,738	(7.2)	27,658	25,713	(7.0)
EBITDA	4,281	3,826	(10.6)	4,831	4,493	(7.0)	5,433	5,061	(6.8)
EBITDA margin (%)	20.1%	19.1%	(104.3)	19.7%	19.8%	4.8	19.6%	19.7%	4.1
PAT	3,024	2,669	(11.7)	3,402	3,149	(7.4)	3,846	3,568	(7.2)
EPS (Rs)	67.1	59.2	(11.7)	75.5	69.9	(7.4)	85.3	79.2	(7.2)


Source: Anand Rathi Research

**Fig 10 – PE Chart**



Source: Bloomberg, Anand Rathi Research

**Fig 11 – PE Chart on Short-Term Mean**



Source: Bloomberg, Anand Rathi Research

### Risks

- Adverse weather in the home market.
- Volatile commodity prices globally.
- Undue delay in ramping up Dahej's technical synthesis plant.


## Appendix

### Analyst Certification

The views expressed in this Research Report accurately reflect the personal views of the analyst(s) about the subject securities or issuers and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. The research analysts are bound by stringent internal regulations and also legal and statutory requirements of the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of Anand Rathi, and have no bearing whatsoever on any recommendation that they have given in the Research Report.

### Important Disclosures on subject companies

#### Rating and Target Price History (as of 5 February 2026)



### Anand Rathi Ratings Definitions

Analysts' ratings and the corresponding expected returns take into account our definitions of Large Caps, Mid Caps & Small Caps as described in the Ratings Table below:

#### Ratings Guide (12 months)

	Buy	Hold	Sell
Large Caps (Top 100 companies)	>15%	0-15%	<0%
Mid Caps (101st-250th company)	>20%	0-20%	<0%
Small Caps (251st company onwards)	>25%	0-25%	<0%

### Research Disclaimer and Disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

Anand Rathi Share and Stock Brokers Ltd. (hereinafter refer as ARSSBL) (Research Entity, SEBI Regn No. INH000000834, Date of Regn. 29/06/2015, BSE Enlistment Number – 5048 date of Regn 25 July 2024 ) is a subsidiary of the Anand Rathi Financial Services Ltd. ARSSBL is a corporate trading and clearing member of Bombay Stock Exchange Ltd (BSE), National Stock Exchange of India Ltd. (NSEIL), Multi Commodity Exchange of India Limited (MCX), National Commodity & Derivatives Exchange Limited (NCDEX), and also depository participant with National Securities Depository Ltd (NSDL) and Central Depository Services Ltd. (CDSL). ARSSBL is engaged into the business of Stock Broking, Depository Participant, Mutual Fund distributor.

The research analysts, strategists, or research associates principally responsible for the preparation of Anand Rathi research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors and firm revenues.

**General Disclaimer:** This Research Report (hereinafter called "Report") is meant solely for use by the recipient and is not for circulation. This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through ARSSBL nor any solicitation or offering of any investment/trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by ARSSBL to be reliable. ARSSBL or its directors, employees, affiliates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views. While due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of ARSSBL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this Report. The price and value of the investments referred to in this Report and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance. ARSSBL does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding taxation aspects of any potential investment.

Opinions expressed are our current opinions as of the date appearing on this Research only. We do not undertake to advise you as to any change of our views expressed in this Report. Research Report may differ between ARSSBL's RAs and/ or ARSSBL's associate companies on account of differences in research methodology, personal judgment and difference in time horizons for which recommendations are made. User should keep this risk in mind and not hold ARSSBL, its employees and associates responsible for any losses, damages of any type whatsoever.

ARSSBL and its associates or employees may; (a) from time to time, have long or short positions in, and buy or sell the investments in/ security of company (ies) mentioned herein or (b) be engaged in any other transaction involving such investments/ securities of company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) these and other activities of ARSSBL and its associates or employees may not be construed as potential conflict of interest with respect to any recommendation and related information and opinions. Without limiting any of the foregoing, in no event shall ARSSBL and its associates or employees or any third party involved in, or related to computing or compiling the information have any liability for any damages of any kind.

Details of Associates of ARSSBL and Brief History of Disciplinary action by regulatory authorities & its associates are available on our website i.e. [www.rathionline.com](http://www.rathionline.com)

**Disclaimers in respect of jurisdiction:** This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject ARSSBL to any registration or licensing requirement within such jurisdiction(s). No action has been or will be taken by ARSSBL in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this Report shall not be possessed, circulated and/or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. ARSSBL requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to ARSSBL. Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in India.

#### Statements on ownership and material conflicts of interest, compensation - ARSSBL and Associates

##### Answers to the Best of the knowledge and belief of ARSSBL/ its Associates/ Research Analyst who is preparing this report

Research analyst or research entity or his associate or his relative has any financial interest in the subject company and the nature of such financial interest.	No
ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report?	No
ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company	No
ARSSBL/its Associates/ Research Analyst/ his Relative have any other material conflict of interest at the time of publication of the research report?	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have managed or co-managed public offering of securities for the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation or other benefits from the subject company or third party in connection with the research report	No
ARSSBL/its Associates/ Research Analyst/ his Relative have served as an officer, director or employee of the subject company.	No
ARSSBL/its Associates/ Research Analyst/ his Relative has been engaged in market making activity for the subject company.	No

#### NOTICE TO US INVESTORS:

This research report is the product of Anand Rathi Share and Stock Brokers Limited, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated person(s) of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances, and trading securities held by a research analyst account.

Research reports are intended for distribution only to Major U.S. Institutional Investors as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act of 1934 (the Exchange Act) and interpretations thereof by the U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a-6(a)(2). If the recipient of this research report is not a Major U.S. Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated, and/or transmitted onward to any U.S. person which is not a Major U.S. Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major U.S. Institutional Investors, Anand Rathi Share and Stock Brokers Limited has entered into a Strategic Partnership and chaperoning agreement with a U.S. registered broker-dealer: Banc Trust Securities USA. Transactions in securities discussed in this research report should be affected through Banc Trust Securities USA.

1. ARSSBL or its Affiliates may or may not have been beneficial owners of the securities mentioned in this report.
2. ARSSBL or its affiliates may have or not managed or co-managed a public offering of the securities mentioned in the report in the past 12 months.
3. ARSSBL or its affiliates may have or not received compensation for investment banking services from the issuer of these securities in the past 12 months and do not expect to receive compensation for investment banking services from the issuer of these securities within the next three months.
4. However, one or more of ARSSBL or its Affiliates may, from time to time, have a long or short position in any of the securities mentioned herein and may buy or sell those securities or options thereon, either on their own account or on behalf of their clients.
5. As of the publication of this report, ARSSBL does not make a market in the subject securities.
6. ARSSBL or its Affiliates may or may not, to the extent permitted by law, act upon or use the above material or the conclusions stated above, or the research or analysis on which they are based before the material is published to recipients and from time to time, provide investment banking, investment management or other services for or solicit to seek to obtain investment banking, or other securities business from, any entity referred to in this report.

© 2026. This report is strictly confidential and is being furnished to you solely for your information. All material presented in this report, unless specifically indicated otherwise, is under copyright to ARSSBL. None of the material, its content, or any copy of such material or content, may be altered in any way, transmitted, copied or reproduced (in whole or in part) or redistributed in any form to any other party, without the prior express written permission of ARSSBL. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of ARSSBL or its affiliates, unless specifically mentioned otherwise.

As of the publication of this report, ARSSBL does not make a market in the subject securities.

Registration granted by SEBI, Enlistment as RA and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Additional information on recommended securities/instruments is available on request.

**Compliance officer:** Deepak Kedia, email id: [deepakkedia@rathi.com](mailto:deepakkedia@rathi.com), Contact no. +91 22 6281 7000

**Grievance officer:** Madhu Jain, email id: [grievance@rathi.com](mailto:grievance@rathi.com), Contact no. +91 22 6281 7191

**ARSSBL registered address:** Express Zone, A Wing, 10th Floor, Western Express Highway, Diagonally Opposite Oberoi Mall, Malad (E), Mumbai – 400097.  
Tel No: +91 22 6281 7000 | Fax No: +91 22 4001 3770 | CIN: U67120MH1991PLC064106.